Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Welcome,         Profile    Billing    Logout  
 84 Trials 
115 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rosenberg, Steven A
NCT01174121: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Recruiting
2
332
US
Young TIL, Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda)
National Cancer Institute (NCI)
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
12/28
12/29
NCT01319565: Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Active, not recruiting
2
102
US
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
National Cancer Institute (NCI)
Metastatic Melanoma, Skin Cancer
06/25
06/26
NCT03412877: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Recruiting
2
270
US
Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA )
National Cancer Institute (NCI)
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
03/27
03/28
NCT04102436: Non-Viral TCR Gene Therapy

Withdrawn
2
210
US
Fludarabine, Cyclophosphamide, Aldesleukin, Sleeping Beauty Transposed PBL
National Cancer Institute (NCI)
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Ovarian Cancer
03/24
03/24
NCT06253520: Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Recruiting
1
210
US
Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
National Cancer Institute (NCI)
Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
06/31
06/33
NCT00923026: Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

Enrolling by invitation
N/A
1000
US
National Cancer Institute (NCI)
Melanoma, Adenocarcinoma, Carcinoma NOS, Neuroendocrine Tumors
 
 
NCT00001823: Evaluation for NCI Surgery Branch Clinical Research Protocols

Recruiting
N/A
7000
US
National Cancer Institute (NCI)
Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
 
 
NCT00068003: Harvesting Cells for Experimental Cancer Treatments

Enrolling by invitation
N/A
7000
US
Anti-CD19 CAR PBL
National Cancer Institute (NCI)
Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
 
 
NCT05600933: Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

Enrolling by invitation
N/A
1200
US
National Cancer Institute (NCI)
Solid Tumors, Hematologic Malignancy, Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma, Pre-Malignancy, Lung Cancer
06/33
06/33
Kreitman, Robert
NCT03340506 / 2017-001987-39: Dabrafenib and/or Trametinib Rollover Study

Recruiting
4
100
Europe, Japan, US, RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
12/27
12/27
NCT00321555: LMB-2 to Treat Hairy Cell Leukemia

Completed
2
15
US
Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
National Cancer Institute (NCI)
Hairy Cell Leukemia
08/16
12/22
NCT01981512: Study of Ibrutinib for Treatment of Relapsed Hairy Cell Leukemia

Recruiting
2
18
US
Ibrutinib
National Cancer Institute (NCI)
Hairy Cell Leukemia
05/17
05/17
NCT01059786: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Checkmark P2 data in HCL
Nov 2011 - Nov 2011: P2 data in HCL
Active, not recruiting
2
69
US
Pentostatin, Nipent, Rituximab, Rituxan, Bendamustine, Bendeka, Treanda, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Epinephrine, Adrenaline, Antihistamines, Corticosteroids, Corticoid, Bronchodilators, Broncholytic, Intravenous (IV) Saline
National Cancer Institute (NCI)
Hairy Cell Leukemia
12/22
12/25
NCT04324112: Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Recruiting
2
45
US
binimetinib, Encorafenib
National Cancer Institute (NCI)
Hairy Cell Leukemia
04/28
07/28
NCT04322383 / 2019-000607-33: Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Recruiting
2
40
US
binimetinib
National Cancer Institute (NCI)
Hairy Cell Leukemia
04/28
07/28
NCT00923013: Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Checkmark P2 data in HCL
Nov 2011 - Nov 2011: P2 data in HCL
Active, not recruiting
2
203
US
Cladribine, Rituximab
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/24
01/30
NCT06311227: Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recruiting
2
20
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
05/27
05/27
NCT00924170: Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Completed
1/2
18
US
LMB-2, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
National Cancer Institute (NCI)
Adult T-Cell Leukemia (ATL)
01/16
05/21
19-C-0042, NCT03805932: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting
1
18
US
Moxetumomab Pasudotox-tdfk, Lumoxiti, Rituximab, Rituxan, Ruxience, Rituximab-pvvr, Dexamethasone, Ozurdex, Maxidex, DexPak 6 Day, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Nytol, Banophen, Famotidine, Pepcid AC, Pepcid, Acid Controller, Aspirin, Ecotrin, Enteric Coated Aspirin, Buffered Aspirin
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/23
06/25
NCT04815356: Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Recruiting
1
27
US
CD22CART cell infusion
National Cancer Institute (NCI)
Hairy Cell Leukemia, Hairy Cell Leukemia Variant
12/36
12/36
NCT01087333: Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Recruiting
N/A
1263
US
National Cancer Institute (NCI)
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
 
 
NCT04362865: Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

Active, not recruiting
N/A
679
US
National Cancer Institute (NCI)
COVID-19
12/25
12/25
Fine, Howard A
NCT04691960: A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging

Recruiting
2
36
US
Ketogenic Diet, Metformin
Weill Medical College of Cornell University
Glioblastoma
12/25
12/25
NCT05183204: Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

Recruiting
2
33
US
Paxalisib, Metformin, Ketogenic Diet
Weill Medical College of Cornell University, Kazia Therapeutics Limited
Glioblastoma
12/24
12/25
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Active, not recruiting
2
300
US
AVD-104, Avacincaptad
Aviceda Therapeutics, Inc.
Geographic Atrophy of the Macula, Macular Degeneration
09/25
09/26
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Active, not recruiting
2
100
US
Active Comparator CT1812, Placebo Comparator
Cognition Therapeutics
Age-Related Macular Degeneration
07/27
08/27
Sportes, Claude
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Camphausen, Kevin A
NCT02709226: Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Completed
1
17
US
Radiation
National Cancer Institute (NCI)
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
12/22
07/23
NCT04216329: Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Active, not recruiting
1
11
US
Selinexor, Xpovio, Temozolomide, Temodar, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Serotonin antagonists, Olanzapine, Zyprexa Relprevv, Zyprexa Zydis, Zyprexa, Salt tablets, Sodium Chloride tablets, Anti-diarrheal, Loperamide, Imodium
National Cancer Institute (NCI)
Gliosarcoma, Newly Diagnosed, Glioblastoma
09/23
07/26
NCT00027326: Collection of Blood and Urine From Patients Undergoing Radiation Therapy

Enrolling by invitation
N/A
720
US
National Cancer Institute (NCI)
Carcinoma, Cancer, Tumor
 
 
NCT00083512: Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Recruiting
N/A
200
US
National Cancer Institute (NCI)
Glioblastoma Multiforme
 
 
NCT00026650: Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy

Recruiting
N/A
700
US
National Cancer Institute (NCI)
Cancer
 
 
Yang, James C
CAURAL, NCT02454933: Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Checkmark CAURAL trial of durvalumab in combination with osimertinib second-line T790M+ NSCLC
Feb 2019 - Feb 2019: CAURAL trial of durvalumab in combination with osimertinib second-line T790M+ NSCLC
Checkmark Of P3 CAURAL trial of Tagrisso + durvalumab in second-line advanced EGFRm T790M NSCLC due to safety/efficacy reason
Apr 2016 - Apr 2016: Of P3 CAURAL trial of Tagrisso + durvalumab in second-line advanced EGFRm T790M NSCLC due to safety/efficacy reason
Completed
3
29
Canada, RoW
AZD9291, MEDI4736
AstraZeneca
Locally Advanced or Metastatic EGFR T790M+ NSCLC
08/17
06/23
NCT04471415 / 2020-002770-27: Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Terminated
2a
61
Europe, US, RoW
DRP-104, atezolizumab
Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc.
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
03/23
03/23
ILLUMINATE, NCT03994393: Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Active, not recruiting
2
100
RoW
Tremelimumab, Durvalumab
University of Sydney, AstraZeneca, Australasian Lung Cancer Trials Group
EGFR Mutant Advanced Non Small Cell Lung Cancer
06/23
01/24
NCT02133196: T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting
2
85
US
Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL
National Cancer Institute (NCI)
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
10/25
10/25
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
NCT04442126 / 2021-000441-41: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Terminated
1/2
52
Europe, US, RoW
NM21-1480
Numab Therapeutics AG
Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
02/24
02/24
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
NCT02830724: Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Recruiting
1/2
124
US
Cyclophosphamide, Fludarabine, Aldesleukin, Anti-hCD70 CAR transduced PBL
National Cancer Institute (NCI)
Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
01/27
01/28
NCT03190941 / 2017-000268-14: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Recruiting
1/2
110
US
Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL, Aldesleukin
National Cancer Institute (NCI)
Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer
06/27
06/28
19-C-0017, NCT03745326: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Recruiting
1/2
70
US
Cyclophosphamide, Fludarabine, Aldesleukin, anti-KRAS G12D mTCR PBL
National Cancer Institute (NCI)
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
12/27
12/28
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
Szabo, Eva
NCT03978000 / 2018-000754-22: IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Active, not recruiting
3
2158
Europe, US, RoW
IBP-9414, Placebo
Infant Bacterial Therapeutics
Necrotizing Enterocolitis
06/24
07/24
NCT04460352 / 2020-000149-15: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Recruiting
3
1020
Europe, Canada
Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Neoadjuvant chemotherapy, Esophagectomy, Neoadjuvant radiotherapy (arm B), Neoadjuvant Platin-Taxane Regimen (alternative 1), Cisplatin, paclitaxel, Platinum-Fluoropyrimidine Regimens (alternative 2a), Oxaliplatin, calcium folinate, 5-fluorouracil, Platinum-Fluoropyrimidine Regimens (alternative 2b)
Karolinska University Hospital, University of Leipzig, The Swedish Research Council
Esophageal Squamous Cell Carcinoma
09/26
12/31
SARONG-II, NCT06115629: Surveillance After Resection of Oesophageal aNd Gastric Cancer () Trial

Not yet recruiting
3
952
Europe
Surveillance protocol
University of Dublin, Trinity College, Trinity St. James's Cancer Institute, University of Oxford, Karolinska Institutet
Esophageal Cancer, Gastric Cancer
11/26
11/29
Libutti, Steven K
NCT04336332: Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

Terminated
2
75
US
Hydroxychloroquine Sulfate + Azithromycin, Hydroxychloroquine, Plaquenil, Z-Pak, Zithromax, Zmax, Hydroxychloroquine Sulfate
Rutgers, The State University of New Jersey
SARS-CoV-2, COVID-19
10/20
10/20
Figg, William D
NCT03436745: The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Completed
1
11
US
Zolpidem
National Cancer Institute (NCI)
Prostatic Neoplasms
01/24
01/24
NCT00341939: Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data

Completed
N/A
484
US
National Cancer Institute (NCI)
Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Lung Cancer, Melanoma
06/24
06/24
NCT00026663: Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance

Completed
N/A
86
US
National Cancer Institute (NCI)
Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma
06/24
06/24
NCT01441089: Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

Recruiting
N/A
1100
US
National Cancer Institute (NCI)
Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
 
 
NCT00923221: Collection of Blood From Patients With Prostate Cancer

Recruiting
N/A
1000
US
National Cancer Institute (NCI)
Cancer Of Prostate, Prostate Cancer, Prostatic Neoplasms, Metastatic Prostate Cancer, Prostate
 
 
NCT02706652: Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients

Enrolling by invitation
N/A
900
US
National Cancer Institute (NCI)
Cancer
12/26
12/26
NCT02810405: Collection of Tissue Blocks or Slides From Patients With Cancer

Completed
N/A
191
US
National Cancer Institute (NCI)
Tumor, Carcinogens, Neoplasm, Benign, Benign Neoplasms, Cancer
08/24
08/24
NCT02154022: Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

Enrolling by invitation
N/A
100
US
National Cancer Institute (NCI)
Cancer, Solid Tumors, Neoplasm
05/29
05/30
Grem, Jean
SOLARIS, NCT04094688: Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer

Active, not recruiting
3
455
US
Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colorectal Adenocarcinoma
01/26
07/26
NCT04141995: FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

Active, not recruiting
2
11
US
Digoxin, Lanoxin, Digitek, Digox, 5Fluorouracil, Adrucil, 5-FU, Calcium Leucovorin, Folinic Acid, Irinotecan, Camptothecin-11, CPT-11, Camptosar, Oxaliplatin, Eloxatin
University of Nebraska, National Cancer Institute (NCI)
Pancreas Cancer, Adenocarcinoma of the Pancreas
02/25
02/25
PCS6422-GI-01, NCT04861987: A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

Completed
1
23
US
PCS6422 and capecitabine
Processa Pharmaceuticals
Advanced Cancer, Refractory Cancer, Tumor Gastric
06/24
09/24
Alexander, H Richard
NCT06057935: A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Recruiting
2
64
US
Pemetrexed, Cisplatin, Carboplatin
Memorial Sloan Kettering Cancer Center
Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
09/28
09/28
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

No Longer Available
N/A
US
Melphalan, Percutaneous Hepatic Perfusion
Delcath Systems Inc.
Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma
 
 
Schrump, David S
NCT02795923: Nivolumab Alone or in Combination With Decitabine/Tetrahydrouridine in Non-small Cell Lung Cancer

Not yet recruiting
2
60
US
Nivolumab, Opdivo, oral decitabine, decitabine, DEC, Dacogen, Tetrahydrouridine, THU
Yogen Saunthararajah
Lung Cancer, Non-small Cell Lung Cancer
12/18
12/18
NCT06654050: Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Not yet recruiting
2
15
US
alrizomadlin
National Cancer Institute (NCI)
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
12/27
12/27
NCT05960773: Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Recruiting
2
15
US
Decitabine/cedazuridine
National Cancer Institute (NCI)
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
12/25
12/26
NCT03233724: Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Terminated
1/2
9
US
Decitabine (DAC), Dacogen, Tetrahydrouridine (THU), Pembrolizumab, Keytruda
National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
10/21
10/21
NCT06694454: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Not yet recruiting
1/2
60
US
azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
National Cancer Institute (NCI)
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
12/31
12/34
NCT05642195: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Suspended
1/2
30
US
Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay
National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
12/33
12/35
NCT05898828: Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Withdrawn
1/2
50
US
Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant, H1299 Cell Lysates
National Cancer Institute (NCI)
Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm, Esophagus Cancer, Neoplasms, Esophageal, Esophageal Cancer (EsC)
08/24
08/24
NCT05375825: Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Not yet recruiting
1
42
US
Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
National Cancer Institute (NCI)
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant, Mesothelin (Msln)
12/24
12/24
NCT00242723: Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Recruiting
N/A
1310
US
National Cancer Institute (NCI)
Malignant Pleural Mesotheliomas NOS, Esophageal Cancers NOS, Lung Cancer NOS, Thoracic Cancers, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura
 
 
NCT04431024: Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Recruiting
N/A
800
US
National Cancer Institute (NCI)
Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS), Mesothelioma
06/38
06/38
Arlen, Philip M
NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Recruiting
2
306
Europe, US
Bortezomib, Dexamethasone, Lenalidomide, Revlimid, Acetaminophen, Diphenhydramine, Montelukast, Carfilzomib, Daratumumab, Autologous Stem Cell Transplant (ASCT)
University of Miami, Amgen, Janssen Pharmaceuticals
Multiple Myeloma
02/27
02/27
Tan, Antoinette R
NCT02942355: Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

Active, not recruiting
2
40
US
anastrozole, Arimidex, Palbociclib, Ibrance
Wake Forest University Health Sciences, Pfizer, Atrium Health Levine Cancer Institute
Female Breast Carcinoma, Breast Cancer
06/26
06/26
ToPCourT, NCT06027268: Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

Recruiting
2
36
US
Trilaciclib, COSELA, Pembrolizumab, KEYTRUDA, Gemcitabine, Gemzar, Carboplatin
Wake Forest University Health Sciences, Merck Sharp & Dohme LLC, G1 Therapeutics, Inc.
Metastatic Triple-Negative Breast Cancer
09/26
03/27
NCT00634634: Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
1/2
52
US
Sorafenib, Nexavar, Letrozole, Femara
Rutgers, The State University of New Jersey, Rutgers Cancer Institute of New Jersey, National Cancer Institute (NCI), Bayer, Novartis Pharmaceuticals
Metastatic Breast Cancer
04/19
04/23
INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting
1/2
90
US, RoW
INX-315, Fulvestrant, faslodex
Incyclix Bio
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
12/25
06/26
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
Kumar, Pallavi P
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
NRG-GY026, NCT05256225: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

Recruiting
2/3
525
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, High-Dose-Rate Vaginal Cuff Brachytherapy, HDR-VCB, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab and Trastuzumab hyaluronidase, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab/Hyaluronidase-oysk, Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20, Trastuzumab-Hyaluronidase-oysk
National Cancer Institute (NCI), NRG Oncology
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Carcinosarcoma
10/27
10/27
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
TARGET-PC, NCT06795529: Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

Not yet recruiting
N/A
400
US
Palliative Care Intervention, "TARGET-PC", Enhanced Usual Care
Massachusetts General Hospital, National Cancer Institute (NCI), Duke University, University of Pennsylvania
Metastatic Breast Cancer
10/29
03/30
Walsh, Thomas J
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
EDIPHY, NCT03648385: Effects of DHEA in Pulmonary Hypertension

Active, not recruiting
2
24
US
DHEA tablet, Dehydroepiandrosterone, Placebo
Rhode Island Hospital
Pulmonary Arterial Hypertension
12/24
12/25
Posadas, Edwin M
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
NCT05534646: Study of Apalutamide with Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Recruiting
2
100
US
Apalutamide, Carotuximab
Edwin Posadas, MD, Enviro Therapeutics, Inc.
Castration-resistant Prostate Cancer
01/27
01/27
IIT2023-02-FREEDLAND-FAST-PRO, NCT05832086: Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Recruiting
2
138
US
Fasting Mimicking Diet (FMD), Standard Anti-Cancer Diet
Stephen Freedland, National Cancer Institute (NCI)
Prostate Adenocarcinoma
09/28
03/29
NCT05567679: A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer

Withdrawn
1
20
US
Tazverik
Edwin Posadas, MD, Epizyme, Inc.
Prostate Cancer
12/25
12/25
DigiSTEPS, NCT03757182: Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients

Active, not recruiting
N/A
80
US
Wearable activity monitor, Fitness tracker, Wearable device, Biosensor
Cedars-Sinai Medical Center
Cancer, Cancer, Metastatic, Neoplasms
12/24
12/24
NCT04763109: Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

Recruiting
N/A
15
US
Whole-body Magnetic Resonance Imaging
Nicole Baca
Neurofibromatosis Type 1
05/25
05/26
Cox, Michael C
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
TRANSCEND-T2D-1, NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Recruiting
3
480
US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Diabetes Type 2
06/26
07/26
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Recruiting
3
300
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Bishop, Michael W
AOST2031, NCT05235165: Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Recruiting
3
250
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Questionnaire Administration, Thoracoscopy, Pleuroscopy, Thoracotomy, incision of Chest Wall, Incision of Thorax
Children's Oncology Group, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma
03/31
03/31
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Previously treated CAR-T patients
Novartis Pharmaceuticals, University of Pennsylvania
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
02/36
02/36
NCT05691478: A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Suspended
2/3
1122
US
Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
03/30
03/30
OSTPDL1, NCT03006848: A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

Completed
2
19
US
Avelumab, MSB0010718C, anti-PD-L1, Questionnaires, PROMIS Pediatric Profile, PROMIS Adult Profile
St. Jude Children's Research Hospital, Pfizer, Gateway for Cancer Research
Osteosarcoma
03/20
03/20
 

Download Options